Search results
Results from the WOW.Com Content Network
The COVID Moonshot is a collaborative open-science project started in March 2020 with the goal of developing an un-patented oral antiviral drug to treat SARS-CoV-2, the virus causing COVID-19. [ 1 ] [ 2 ] COVID Moonshot researchers are targeting the proteins needed to form functioning new viral proteins . [ 3 ]
In unvaccinated high-risk people with COVID‑19, nirmatrelvir/ritonavir can reduce the risk of hospitalization or death by 88% if taken within five days of symptom onset. [154] People who take nirmatrelvir/ritonavir also test negative for COVID‑19 about two and a half days earlier than people who do not. [155]
Ensitrelvir is being studied for its potential use as post-exposure prophylaxis (PEP) after SARS-CoV-2 exposure. [19] [20] The SCORPIO-PEP trial is a global Phase 3 trial that will evaluate the safety and efficacy of the drug in preventing symptomatic SARS-CoV-2 infection in household contacts of people who tested positive for COVID-19.
The development of COVID-19 tests was a major public health priority during the early months of the COVID-19 pandemic. In January 2020, scientists from China published the first genetic sequences of SARS-CoV-2 via virological.org, [3] a "hub for prepublication data designed to assist with public health activities and research". [4]
U.S. regulators on Thursday approved the first drug to treat COVID-19: remdesivir, an antiviral medicine given to hospitalized patients through an IV.
Part of a series on the COVID-19 pandemic Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November ...
If you recently tested positive for COVID-19, you may be eligible for antiviral treatments to help reduce your infection. Earlier this year, when the omicron variant was steering the pandemic ...
Researchers at Boston’s Dana-Farber Cancer Institute are working on a drug that takes one of the virus’s most dangerous traits — its talent for mutation — and turns it back on itself.